

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
In re the Application of: COHN and CARSON

Application No.: NOT YET ASSIGNED

Filed: September 8, 2000

For: **Methods of Treating and Preventing Congestive Heart Failure With
Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate**

Attorney Docket No.: 102258.288

Assistant Commissioner of Patents
Washington, DC 20231

Wt
10-12-00
#2
Jc893 U.S. PTO
09/658261
09/08/00

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 form.


The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art.

A copy of each of the documents listed on the attached PTO-1449 form is submitted herewith.

This Information Disclosure Statement is being submitted concurrently with the application. Accordingly, no fee is due.

Applicants respectfully request that the Examiner initial and return a copy of the enclosed PTO-1449 form with the next communication from the Patent Office.

Respectfully submitted,


Edward D. Grieff
Registration No. 38,898

Date: September 8, 2000
HALE and DORR LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: (202) 942-8400